The preliminary safety findings from a Phase 1B clinical trial involving VRON-0200, a groundbreaking immunotherapy for chronic hepatitis B (HBV), were recently highlighted.

In a recent phase 1b clinical trial, patients received multiple injections of a novel immunotherapy, CAN-3110, developed by Candel Therapeutics.

MapLight Therapeutics has initiated a Phase 1 clinical trial for ML-007/PAC, a novel combination therapy aimed at treating schizophrenia and Alzheimer's disease psychosis.

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. have announced an exclusive license agreement for the development and commercialization of Xilio's tumor-activated IL-12 program, XTX301.

Aeovian Pharmaceuticals, focused on creating innovative therapeutics that target the mTORC1 pathway, has initiated its Phase 1 clinical trial for AV078.

Aurion Biotech has commenced a Phase 1/2 clinical trial for AURN001, a novel cell therapy addressing corneal edema due to endothelial dysfunction.

Neurocrine Biosciences has launched a Phase 1 clinical trial for NBI-1065890, an experimental oral medication.

The data reveal that the experimental AZR-MD-001 has shown lasting effects in enhancing the ocular symptoms of Meibomian Gland Dysfunction (MGD) after a six-month treatment period.

The innovative gene therapy ABBV-RGX-314 is poised to set a new benchmark in the treatment of wet age-related macular degeneration (AMD).

Ocean Biomedical has expressed its congratulations to its joint venture (JV) partner, Virion Therapeutics.

The proceeds from this offering will fund Stoke's R&D activities, especially for their Dravet syndrome candidate STK-001, preclinical development of ophthalmology candidate STK-002, and other pipeline projects.

PassPort Technologies, Inc. has reported favorable preliminary outcomes from a Phase 1 clinical trial of their Zolmitriptan PassPort® system.